Market News & Trends
AREV Life Sciences Advances Developments, New Appointments & Relationships
AREV Life Sciences Global Corp. recently announced its new corporate acquisitions and maturation of multiple product lines that are being matched with appointments and expanding…
Spero Therapeutics Announces Positive Topline Results From Phase 1 Bronchoalveolar Lavage Clinical Trial
Spero Therapeutics, Inc. recently announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate.…
Hillstream BioPharma Receives Orphan Drug Designation for Uveal Melanoma Treatment
Hillstream BioPharma Inc. recently announced the FDA granted Orphan Drug Designation to HSB-1216 for Uveal Melanoma (UM). Hillstream continues to….
Adial Pharmaceuticals Announces Closing of $10 Million Financing
Adial Pharmaceuticals, Inc. recently announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately….
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
Skye Bioscience, Inc. recently announced it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ophthalmic nanoemulsion in support of the company’s….
Rhythm Pharmaceuticals Announces Positive Interim Data From Long-Term Extension Study
Rhythm Pharmaceuticals, Inc. recently announced positive interim data from its long-term extension study evaluating setmelanotide in patients with Bardet-Biedl Syndrome (BBS). Rhythm will review these…
Revive Therapeutics Receives FDA Orphan Drug Designation
Revive Therapeutics Ltd. recently announced the US FDA has granted Orphan Drug Designation (ODD) for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver…
Catalent Expands Temperature-Controlled Clinical Supply Capabilities in Shanghai, China
Catalent recently announced it plans to expand its Waigaoqiao Free Trade Zone (FTZ) facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution…
BioXcel Therapeutics Presents Positive Data From Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer
BioXcel Therapeutics, Inc. recently announced results from its ongoing Phase 2 trial of BXCL701, the company's investigational, oral innate immunity activator, in metastatic castration-resistant prostate…
Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children With Congenital Hyperinsulinism
Zealand Pharma A/S recently announced completion of patient enrollment in the second Phase 3-trial, 17103, of dasiglucagon for the treatment of Congenital hyperinsulinism (CHI) in….
Neurocentria Obtains FDA Approval to Conduct Pivotal Phase 2b/3 Clinical Trial for Testing Safety & Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD
Neurocentria Inc. has recently received FDA approval to conduct a pivotal Phase 2b/3 human clinical trial to test the efficacy and safety of its leading…
OKYO Pharma Announces Successful Completion of Pre-IND Meeting With FDA on the Development of OK-101 to Treat Dry Eye Disease
OKYO Pharma Limited recently announced the successful completion of a pre-IND (Investigational New Drug) meeting with the US FDA regarding the development plans for OK-101…
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
Cerevel Therapeutics recently announced positive results from its Phase 1 healthy volunteer clinical trial to evaluate darigabat, a novel alpha-2/3/5 selective GABAA receptor positive allosteric modulator….
AC Immune & Janssen Pharmaceuticals Report Interim Results for Phase 2 Tau Vaccine Program
AC Immune SA recently announced new interim 10-week data from the high-dose cohort of a placebo-controlled Phase 1b/2a trial evaluating ACI-35.030, a first-in-class phosphorylated-Tau (pTau) vaccine candidate in….
PDS Biotech Announces Clinical Trial With Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head & Neck Cancer
PDS Biotechnology Corporation recently announced the initiation of an Investigator-Initiated Trial (ITT), MC200710, for PDS0101 alone or in combination with the checkpoint inhibitor, KEYTRUDA, in patients…
Integrity Bio & LakePharma Become Curia
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, recently announced that Integrity Bio and LakePharma, two companies that it acquired….
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Revive Therapeutics Ltd. recently provided an update on the company’s US FDA Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of….
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio
Collegium Pharmaceutical, Inc. and BioDelivery Sciences International, Inc. recently announced a definitive agreement pursuant to which Collegium will acquire BDSI for….
Pardes Biosciences Presents Interim Clinical Data From Ongoing PBI-0451 Phase 1 Trial
Pardes Biosciences, Inc. recently announced interim clinical data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers has been made available to registered…
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention & Treatment of Influenza
Cidara Therapeutics, Inc. recently announced the US FDA has accepted its Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 –…
